Cytosorbents (NASDAQ: CTSO) reported Q4 EPS of ($0.03), $0.02 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $9.15 million versus the consensus estimate of $10.25 million.

For earnings history and earnings-related data on Cytosorbents (CTSO) click here.